Overview

Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This randomized trial is comparing a standard neoadjuvant chemotherapy with a genomic driven chemotherapy in patients with breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Collaborator:
Institut Curie
Treatments:
Docetaxel